The Impact of Asthma and Chronic Obstructive Pulmonary Disease (COPD) on Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE).
Journal
ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
30
05
2020
accepted:
19
11
2020
pubmed:
21
2
2021
medline:
21
2
2021
entrez:
20
2
2021
Statut:
ppublish
Résumé
Risk of asthma and chronic obstructive pulmonary disease (COPD) may be elevated in systemic lupus erythematosus (SLE), but little research has studied the impact of these conditions on SLE outcomes. We examined prevalence, incidence, and impact of self-reported asthma and COPD in two US-based SLE cohorts (FORWARD and Lupus Outcomes Study [LOS]). Prevalence of asthma and COPD were defined as presence of conditions at individuals' first interviews; incidence was defined as new reports over the next 3 years. Cross-sectional associations of asthma/COPD with patient-reported outcomes (PROs) and longitudinal analyses associations with asthma/COPD at entry with PROs 3 years later were examined. In FORWARD, 19.8% and 8.3% participants reported asthma and COPD, respectively, at entry. In LOS, 36.0% reported the presence of either (US population comparisons: asthma, 9.7%; COPD, 6.1%). Cross-sectionally, asthma/COPD was associated with worse PROs, including disease activity. In FORWARD, individuals with asthma experienced greater worsening of fatigue, pain, and global health ratings longitudinally; individuals with COPD experienced greater increases in self-reported SLE activity. However, no such patterns were noted in the LOS. Asthma and COPD appeared to be more common in SLE than in the general US population and were associated with worse status on PROs cross-sectionally. Asthma was linked to decrements in PROs longitudinally.
Sections du résumé
BACKGROUND
BACKGROUND
Risk of asthma and chronic obstructive pulmonary disease (COPD) may be elevated in systemic lupus erythematosus (SLE), but little research has studied the impact of these conditions on SLE outcomes. We examined prevalence, incidence, and impact of self-reported asthma and COPD in two US-based SLE cohorts (FORWARD and Lupus Outcomes Study [LOS]).
METHODS
METHODS
Prevalence of asthma and COPD were defined as presence of conditions at individuals' first interviews; incidence was defined as new reports over the next 3 years. Cross-sectional associations of asthma/COPD with patient-reported outcomes (PROs) and longitudinal analyses associations with asthma/COPD at entry with PROs 3 years later were examined.
RESULTS
RESULTS
In FORWARD, 19.8% and 8.3% participants reported asthma and COPD, respectively, at entry. In LOS, 36.0% reported the presence of either (US population comparisons: asthma, 9.7%; COPD, 6.1%). Cross-sectionally, asthma/COPD was associated with worse PROs, including disease activity. In FORWARD, individuals with asthma experienced greater worsening of fatigue, pain, and global health ratings longitudinally; individuals with COPD experienced greater increases in self-reported SLE activity. However, no such patterns were noted in the LOS.
CONCLUSION
CONCLUSIONS
Asthma and COPD appeared to be more common in SLE than in the general US population and were associated with worse status on PROs cross-sectionally. Asthma was linked to decrements in PROs longitudinally.
Identifiants
pubmed: 33609085
doi: 10.1002/acr2.11212
pmc: PMC8063140
doi:
Types de publication
Journal Article
Langues
eng
Pagination
221-230Subventions
Organisme : Bristol Myers Squibb
Organisme : NIH/NIAMS
ID : 053308
Informations de copyright
© 2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
Clin Rheumatol. 2015 Nov;34(11):1885-92
pubmed: 26188616
Curr Opin Rheumatol. 2016 Sep;28(5):497-505
pubmed: 27428889
J Cardiopulm Rehabil Prev. 2010 Mar-Apr;30(2):126-36
pubmed: 19952768
PLoS One. 2014 Mar 12;9(3):e91821
pubmed: 24622340
Arthritis Rheum. 2008 Jan 15;59(1):136-43
pubmed: 18163398
J Rheumatol. 2004 Oct;31(10):1896-902
pubmed: 15468350
Clin Rheumatol. 2017 Mar;36(3):555-562
pubmed: 27848056
J Rheumatol. 2003 Jun;30(6):1215-21
pubmed: 12784392
Am J Med. 2009 Aug;122(8):778.e9-15
pubmed: 19635280
Rheumatology (Oxford). 2011 Jan;50(1):16-24
pubmed: 20566735
NCHS Data Brief. 2011 Jun;(63):1-8
pubmed: 22142836
J Rheumatol. 2005 Sep;32(9):1706-8
pubmed: 16142864
PLoS One. 2015 Aug 17;10(8):e0134451
pubmed: 26280671
Arthritis Care Res (Hoboken). 2011 Oct;63(10):1357-64
pubmed: 21702085
Arthritis Rheum. 2004 Mar;50(3):849-57
pubmed: 15022327
Arthritis Rheum. 2008 Apr 15;59(4):465-73
pubmed: 18383406
BMC Public Health. 2013 Jan 09;13:16
pubmed: 23302258
Am J Respir Crit Care Med. 2014 Feb 15;189(4):496-9
pubmed: 24528323
Lupus. 2017 Sep;26(10):1095-1100
pubmed: 28406053
J Rheumatol. 2011 Jun;38(6):1113-22
pubmed: 21285161
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52
pubmed: 22588748
Rheum Dis Clin North Am. 2009 Nov;35(4):819-27, x
pubmed: 19962626
J Rheumatol. 2006 Oct;33(10):1942-51
pubmed: 16960928
Arthritis Care Res (Hoboken). 2019 Jun;71(6):735-741
pubmed: 30354033
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S297-307
pubmed: 22588752
Respir Med. 2018 Jul;140:82-86
pubmed: 29957286
Am J Med. 2008 Sep;121(9):789-96
pubmed: 18724969
Ann Rheum Dis. 2018 Feb;77(2):196-202
pubmed: 28988206
Arthritis Rheumatol. 2016 Feb;68(2):441-8
pubmed: 26359794
Eur Respir J. 2003 Sep;22(3):462-9
pubmed: 14516136
Autoimmun Rev. 2016 May;15(5):487-91
pubmed: 26851551
Respir Med. 2018 Aug;141:47-51
pubmed: 30053971
Arthritis Care Res (Hoboken). 2015 May;67(6):865-72
pubmed: 25186344
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S263-86
pubmed: 22588750
Int J Clin Pharm. 2018 Jun;40(3):573-579
pubmed: 29542033
Lupus. 2003;12(4):280-6
pubmed: 12729051